Make Better Decisions

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
Deloitte
Farmers Insurance
Baxter
Medtronic
Julphar
Cipla
Novartis
US Army
Citi

Generated: January 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,596,756

« Back to Dashboard

Which drugs does patent 6,596,756 protect, and when does it expire?

Patent 6,596,756 protects CYMBALTA and is included in one NDA.

Protection for CYMBALTA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirteen patent family members in fourteen countries.
Summary for Patent: 6,596,756
Title: Treatment of fibromyalgia
Abstract:A method of using N-methyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine to treat persistent pain.
Inventor(s): Goldstein; David Joel (Indianapolis, IN), Iyengar; Smriti (Carmel, IN), Simmons; Rosa Marie Ademe (Carmel, IN)
Assignee: Eli Lilly and Company (Indianapolis, IN)
Application Number:09/786,836
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 6,596,756

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Lilly CYMBALTA duloxetine hydrochloride CAPSULE, DELAYED REL PELLETS;ORAL 021427-001 Aug 3, 2004 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Lilly CYMBALTA duloxetine hydrochloride CAPSULE, DELAYED REL PELLETS;ORAL 021427-002 Aug 3, 2004 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Lilly CYMBALTA duloxetine hydrochloride CAPSULE, DELAYED REL PELLETS;ORAL 021427-004 Aug 3, 2004 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,596,756

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany199 31 989Sep 09, 1999
PCT Information
PCT FiledSeptember 10, 1999PCT Application Number:PCT/US99/20986
PCT Publication Date:March 23, 2000PCT Publication Number: WO00/15223

International Patents Family Members for US Patent 6,596,756

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 449603 ➤ Subscribe
Australia 1197200 ➤ Subscribe
Australia 746887 ➤ Subscribe
Brazil 9913671 ➤ Subscribe
Canada 2344057 ➤ Subscribe
China 1149991 ➤ Subscribe
China 1316904 ➤ Subscribe
Cyprus 1110581 ➤ Subscribe
Germany 69941712 ➤ Subscribe
Denmark 1113797 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Fuji
AstraZeneca
Medtronic
Boehringer Ingelheim
Deloitte
Dow
Colorcon
Daiichi Sankyo
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot